Patients suffering from malignant brain tumors are burdened with a grim prognosis. The blood brain barrier is considered a primary obstacle in therapeutic drug delivery to the brain. Intra-arterial (IA) delivery of therapeutic agents following osmotic BBB opening has been attempted for years, but high variability has limited its widespread implementation. It has been recently shown in animal studies that MRI is superior to X-ray for guiding IA infusions, as it allows direct visualization of the brain parenchyma perfused and facilitates predictable drug targeting. Moreover, PET imaging has revealed that IA, not intravenous, delivery of bevacizumab results in brain accumulation, providing strong rationale for utilizing the IA route. Here, we present our experience in a patient with recurrent butterfly glioblastoma enrolled in first-in-man MRI-guided neurointervention for targeted IA drug delivery.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Republished with permission from BMJ Case Reports Published 27 January 2019; doi: 10.1136/bcr-2018-014469
Contributors MZ: planned treatment and performed procedure, analyzed data and edited manuscript. JW: planned treatment and edited manuscript. BK: planned treatment and edited manuscript. KK: planned treatment and took care of patient on daily basis. MSP and MS: prepared virtual reality visualization. PW: planned procedure, analyzed data, edited manuscript and prepared figures. MJ: planned treatment and performed procedure, analyzed data, drafted manuscript and approved its final form.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Ethics approval Central Clinical Hospital of Ministry of the Interior and Administration.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement All imaging data can be shared on request.
Patient consent for publication Not required.